MST estimates assume that positive results in trofinetide’s Phase 3 trials and NNZ-2591’s Phase 2 trial will trigger milestone payments over CY21-CY23 of ~A$146m, almost equal to its current market cap.
Honestly, I can’t follow this analyst.
Firstly, my understanding was that there will be 3 Phase 2 trials of NNZ-2591 run simultaneously, so why use of the singular “trial”?
Secondly, why would the analyst consider that success in Phase 2 with NNZ-2591 will trigger milestone payments when Neuren hasn’t signed any deal for NNZ-2591?
Updated MST report - target of $3.68 a share, page-3
-
- There are more pages in this discussion • 217 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.795B | |||
| Open | High | Low | Value | Volume |
| $14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $13.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.07 | 6644 | 4 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |